AzTrials
AzTrials

Abdominal Aortic AneurysmNCT06969729

Evaluation of Clinical Efficacy and Safety of Aortal Stent-Graft Created Using 3D Printing Technology

A study testing Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided) in people with Abdominal Aortic Aneurysm and Juxtarenal Abdominal Aortic Aneurysm, run by Samodzielny Publiczny Szpital Kliniczny nr 2 PUM at 1 site in Poland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

the comparison of physician-modified stent-graft created in 3D models versus custom-made devices in the treatment of complex abdominal aortic aneurysm Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 sitePoland
Study dates
1 Nov 2022to 30 Apr 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Female and male subjects age ≥ 18 2. Subject need to meet one of the following criteria:
  • Subjects with juxtarenal or suprarenal abdominal aortic aneurysm, type IV thoracoabdominal aneurysm of diameter >5.5cm (male) and 5.2cm (female)
  • Subjects with juxtarenal or suprarenal abdominal aortic aneurysm, type IV thoraco-abdominal aneurysm with aneurysm growth rate ≥ 0.5cm during 6 months
  • Type IA endoleak of post-implantation of abdominal stent- graft 3. Iliac arteries morphology with aortic stent graft implantation to be restored 4. Aortic segment which is proximal to aneurysm
  • Length ≥20mm
  • Diameter 20mm-36mm
  • Aortic suprarenal angle ≤75 degrees 5. Survival > 2 years

Who cannot join

  • Female and male subjects age <18
  • Pregnancy and breast feeding
  • Allergy and hypersensitivity to matherials of which the stent- graft is composed
  • Hypersensitivity and contraindication to anti coagulation or contrast application to angio - CT which cannot be eliminated medically
  • Coagulopathy which cannot medically treated
  • Active infection which might cause stent - graft infection
Show all 18Show fewer
  • Creatinine level > 3.0mg/dL
  • Marphan syndrome, Ehlers - Denlos syndrome
  • Unstable angina pectoris
  • Raptured aortic aneurysm caused by cardiac insufficiency
  • Unwillingness to comply with protocol procedures
  • Iliac arteries morphology adequate for stent-graft implantation
  • The diameter of the aortic flow lumen in reno-visceral aorta greater than 34mm
  • Aortic section which is proximal to celiac artery with significant number of thrombi, calcification or changed by aneurysm
  • Aorta with significant number of irregular thrombi which may lead to embolism ("shaggy aorta")
  • Diameter of proximal kidney arteries which is exercisable to stenting <4.5mm
  • Devision of kidney artery which is exercisable to stenting in the distance of <1cm of celiac artery, each of them is is in <4.5mm in diameter
  • Atypical anatomy of celiac artery in the form of separate exit of splenic and hepatic aortic artery

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Poland1 site, 1 recruiting
  • An Independent Clinical Hospital 2 PUM

    Szczecin, West Pomeranian Voivodeship, 70-111

    Pawel Rynio, MD PHD, +914661156, p.rynio@spsk2-szczecin.pl

    Recruiting

Other trials in Poland

About this study

Official title: Evaluation of Clinical Efficacy and Safety of Aortal Stent-graft Modelled Printing 3D Model Printing Technology - Multicenter, Randomized Clinical Trial

the comparison of physician-modified stent-graft created in 3D models versus custom-made devices in the treatment of complex abdominal aortic aneurysm

Read the detailed description

This is randomized, multicenter, open-label, 2 -arm Study to evaluate the efficacy and safety in stent-graft application of arm A and Arm B in patients with juxtarenal or pararenal abdominal aortic aneurysm, thoracic-abdominal aneurysm type IV or type IA endoleak.

Approximately 100 eligible patients will be randomized in a 1:1 ratio into 2 arms (n=50 in each arm) Arm A treated with innovative angiosurgery intervention Arm B standard procedure Study will use an Interactive Web Response System (IWRS) for randomization. Randomization will be used to minimize bias in the assignment of subjects to treatment groups, to increase the likelihood that known and unknown subject attributes (e.g. demographic and baseline characteristics) are evenly balanced, and to enhance the validity of statistical comparisons across treatment groups.

Subjects will be randomized based on following stratification: • Site

  • Aneurysm class Subject participation will include a Screening Phase, Intervention Phase, Safety follow-up and End of Study.

The screening phase will last up to 28 days before the therapeutic intervention periods starts (two hospitalizations finished with 2 angio surgery intervention) during which the subject's eligibility and baseline characteristics will be determined. The therapeutic intervention will last from randomization until second hospitalization will end with angio surgery intervention). There will be 2 follow up visits. Safety follow up will lasts 12 months.

Aorta assessment by angio CT will be performed at screening, intervention period at hospitalization no. 1 and in 30 day follow up, 12 month follow up

Being tested
Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)
Keywords
AAA, physician-modified stent-graft, custom-made device, complex abdominal aortic aneurysm, juxtarenal abdominal aortic aneurysm, pararenal abdominal aortic aneurysm, thoracoabdominal aortic aneurysm, endovascular aneurysm repair, 3D printing, 3D model, PMEG, type IA endoleak, aortic stent-graft, PMSG, patient-specific 3D model, complex aortic pathology
Medical subject headings
Aortic Aneurysm, Abdominal, Aortic Aneurysm, Thoracoabdominal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)Procedure or surgery

    Implantation of a physician-modified fenestrated stent-graft using a patient-specific 3D-printed aortic template, performed via an endovascular approach.

Study groups in NCT06969729
Study groupRoleWhat they receive
Physician-Modified Stent-Grafts Made Using 3D Aortic TemplateExperimentalPatients with aortic pathology undergoing implantation of physician-modified stent-grafts created using a patient-specific 3D-printed aortic template.
Receives: Procedure: Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)
Custom-Made Fenestrated Stent-GraftActive comparatorImplantation of a commercially manufactured, patient-specific custom-made fenestrated stent-graft via an endovascular approach.
Receives: Procedure: Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Surviving at 1 Year Without Aortic Rupture

    Rupture - free one year survival. The number of participants who remain alive and free from aortic rupture at 1 year following stent-graft implantation. Rupture will be defined as radiologically confirmed loss of aortic wall integrity with associated clinical symptoms.

    Measured: 1 year

  2. Number of Participants Surviving at 30 Days Post-Procedure (Perioperative Survival)

    The number of participants who are alive 30 days after the stent-graft procedure. Deaths from any cause within 30 days post-implantation will be counted.

    Measured: 30 days

Secondary outcomes (8)
  1. Number of Deaths from Any Cause Within 1 Year

    Total number of participant deaths due to any cause occurring within one year of the procedure.

    Measured: 1 year

  2. Number of Cardiovascular-Related Deaths Within 1 Year

    The number of participant deaths attributed to cardiovascular causes (e.g., myocardial infarction, stroke, aortic rupture) within 1 year of the procedure, as adjudicated by the study investigators.

    Measured: 1 year

  3. Number of Participants Without Aneurysm Growth at 1 Year

    The number of participants whose aneurysm size remains stable (no increase >5 mm in maximum diameter) as assessed by imaging (e.g., CT angiography) at 1 year post-implantation.

    Measured: 1 year

  4. Number of Participants Surviving Without Reintervention at 1 Year

    The number of participants who do not require any secondary endovascular or surgical intervention related to the index aortic pathology within 1 year of the initial procedure.

    Measured: 1 year

  5. Change in Incidence of Cardiovascular Events at 1 Year

    Change in the number of participants experiencing cardiovascular events (e.g., myocardial infarction, stroke, cardiac arrest) compared to baseline rates or historical controls over a 1-year follow-up period.

    Measured: 1 year

  6. Number of Deaths from Any Cause at 1 Year (Overall Mortality)

    The total number of participant deaths from any cause within one year of the stent-graft procedure.

    Measured: 1 year

  7. Change in Renal Function at 1 Year

    Change in estimated glomerular filtration rate (eGFR) or serum creatinine level from baseline to 1 year post-procedure, used to assess renal function.

    Measured: 1 year

  8. Total Cost of Treatment at 1 Year

    Cumulative healthcare cost per participant associated with the initial stent-graft procedure, hospitalization, follow-up visits, imaging, medications, and any reinterventions within 1 year.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2025
  2. Study start1 Nov 2022
  3. Primary completion30 Apr 2027 (estimated)
  4. Study completion30 Apr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be randomized in a 1:1 ratio to one of two parallel treatment arms. Arm A will receive treatment with physician-modified stent-grafts created using 3D models, and Arm B will receive treatment with custom-made devices. Outcomes will be compared between the two groups during follow-up.
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06969729
Sponsor's protocol ID
2020/ABM/01/00121/P/02
Status last verified
Apr 2026
First submitted
14 Jan 2023
Last updated
16 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data (IPD) will not be shared due to institutional data governance policies and applicable data protection regulations, including the General Data Protection Regulation (GDPR) and national laws. These frameworks restrict the sharing of detailed clinical data with external parties to ensure the confidentiality and security of participant information.

Publications

  • Rynio P, Jedrzejczak T, Rybicka A, Milner R, Gutowski P, Kazimierczak A. Initial Experience with Fenestrated Physician-Modified Stent Grafts Using 3D Aortic Templates. J Clin Med. 2022 Apr 13;11(8):2180. doi: 10.3390/jcm11082180.

    PubMed 35456273

Questions about this trial

What is this clinical trial studying?

A study testing Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided) in people with Abdominal Aortic Aneurysm and Juxtarenal Abdominal Aortic Aneurysm, run by Samodzielny Publiczny Szpital Kliniczny nr 2 PUM at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Pawel Rynio (914661156, p.rynio@spsk2.szczecin.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Surviving at 1 Year Without Aortic Rupture (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06969729, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in